Clinical Trial of Sinudrain Haft Bahr Solution for Symptom Management in Mild to Moderate COVID-19
Archives of Advances in Biosciences,
Vol. 15 No. 1 (2024),
24 January 2024
,
Page 1-11
https://doi.org/10.22037/aab.v15i1.47585
Abstract
Introduction: The COVID-19 pandemic, caused by the coronavirus, has been declared a global health emergency by the World Health Organization (WHO). This virus primarily affects the respiratory system, and affordable treatments for mild to moderate cases are urgently needed. Sinudrain Haft Bahr, a solution with antiseptic properties, was evaluated for its potential to alleviate COVID-19 symptoms.
Materials and Methods: A clinical trial was conducted on 61 COVID-19 patients at Taleghani Hospital, Tehran. After a medical evaluation and analysis of symptoms, participants were randomized 1:1 (intervention vs. control) using admission code parity. The intervention group received Sinudrain, while the control group received routine medications from the national protocol. The drug was administered by gargling the solution three times a day and spraying it inside the nose six times a day. Patients' clinical symptoms were monitored on the first, third, and fifth days.
Results: Sinudrain significantly reduced cough (45%), sore throat (41%), and shortness of breath (32%) versus controls (all p<0.05). No effect was observed on fever, loss of smell, or digestive symptoms.
Conclusion: Sinudrain is a promising adjunctive therapy for COVID-19 respiratory symptoms, with advantages in cost, availability, and safety. Further trials are warranted.
- COVID-19
- Sinudrain Haft Bahr
- randomized controlled trial
- respiratory symptoms
- nasal spray
- adjunctive therapy
How to Cite
References
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD. A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature. 2020 Mar 12;579(7798):270-3.
[DOI: 10.1038/s41586-020-2012-7]
WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020 Ghebreyesus, T. A. (2020, March 11). WHO Director-General's opening remarks at the media briefing on COVID-19. [LINK]
Heymann DL, Shindo N. COVID-19: what is next for public health?. The lancet. 2020 Feb 22;395 (10224):542-5.
[DOI:10.1016/s0140-6736(20)30374-3]
Janet V Diaz, (2023). Living guidance for clinical management of COVID-19 WHO. [LINK]
Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, Salanti G, Low N. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS medicine. 2020 Sep 22;17(9): e1003346. [DOI:10.1371/journal.pmed.1003346]
Cordon-Cardo C, Pujadas E, Wajnberg A, Sebra R, Patel G, Firpo-Betancourt A, Fowkes M, Sordillo E, Paniz-Mondolfi A, Gregory J, Krammer F. COVID-19: staging of a new disease. Cancer Cell. 2020 Nov 9;38(5):594-7.
[DOI:10.1016/j.ccell.2020.10.006]
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020 Feb 15;395(10223):497-506.
[DOI:10.1016/s0140-6736(20)30183-5]
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Yu T. Epidemiolo-gical and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet. 2020 Feb 15;395(10 223):507-13.
[DOI: 10.1016/s0140-6736(20)30211-7]
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. jama. 2020 Mar 17;323(11):1061-9.
[DOI:10.1001/jama.2020.1585]
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du B. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020 Apr 30;382(18):1708-20.
[DOI:10.1056/nejmoa2002032]
Spinato G, Fabbris C, Polesel J, Cazzador D, Borse -tto D, Hopkins C, Boscolo-Rizzo P. Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection. Jama. 2020 May 26;323(20):2089-90. [DOI:10.1001/jama.2020.6771]
Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, Rusconi S, Gervasoni C, Ridolfo AL, Rizzardini G, Antinori S. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study. Clinical infectious diseases. 2020 Jul 28;71(15):889-90.
[DOI:10.1093/cid/ciaa330 ]
Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis. Otolaryngology–Head and Neck Surgery. 2020 Jul;163(1):3-11.
[DOI: 10.1177/0194599820926473]
Chavda VP, Baviskar KP, Vaghela DA, Raut SS, Bedse AP. Nasal sprays for treating COVID-19: a scientific note. Pharmacological Reports. 2023 Apr;75(2):249-65. [DOI:10.1007/s43440-023-00463-7]
Xi J, Lei LR, Zouzas W, April Si X. Nasally inhaled therapeutics and vaccination for COVID‐19: Developments and challenges. MedComm. 2021 Dec;2(4):569-86. [DOI:10.1002/mco2.101]
Chavda VP, Vora LK, Pandya AK, Patravale VB. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. Drug discovery today. 2021 Nov 1;26(11):2619-36. [DOI:10.1016/j.drudis.2021.07.021]
Mitchell JP, Berlinski A, Canisius S, Cipolla D, Dolovich MB, Gonda I, et al. Urgent appeal from international society for aero sols in medicine (ISAM) during COVID-19: clinical decision makers and governmental agencies should consider the inhaled route of administration: a statement from the ISAM regulatory and standardization issues networking group. J Aerosol Med Pulm Drug Deliv. 2020; 33:235–8. [DOI:10.1089/jamp.2020.1622]
Paull JR, Luscombe CA, Castellarnau A, Heery GP, Bobardt MD, Gallay PA. Protective effects of astodrimer sodium 1% nasal spray formulation against SARS-CoV-2 nasal challenge in K18-hACE2 mice. Viruses. 2021 Aug 20;13(8):1656. [DOI:10.3390/v13081656]
UK Clinical Trial Confrms SaNOtize’s Breakthrough Treatment for COVID-19 2021. [LINK]
Covis Pharma S.à.r.l. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efcacy of Ciclesonide Metered-Dose Inhaler in Non-hos pitalized Patients 12 Years of Age and Older with Symptomatic COVID-19 Infection. clinicaltrials. gov; 2022. [LINK]
Xu W, Xia S, Pu J, Wang Q, Li P, Lu L, Jiang S. The antihistamine drugs carbinoxamine maleate and chlorpheniramine maleate exhibit potent antiviral activity against a broad spectrum of influenza viruses. Frontiers in microbiology. 2018 Nov 6;9:2643.[DOI:10.3389/fmicb.2018.02643]
Torres J, Go CC, Chohan FA, Sanchez-Gonzalez MA, Ferrer G. Chlorpheniramine maleate nasal spray in COVID-19 patients: Case Series.[LINK]
Aref ZF, Bazeed SE, Hassan MH, Hassan AS, Rashad A, Hassan RG, Abdelmaksoud AA. Clinical, biochemical and molecular evaluations of ivermectin mucoadhesive nanosuspension nasal spray in reducing upper respiratory sympto -ms of mild COVID-19. International journal of nanomedicine. 2021 Jun 15:4063-72. [DOI:10.2147 /ijn.s313093]
Guenezan J, Garcia M, Strasters D, Jousselin C, Lévêque N, Frasca D, Mimoz O. Povidone iodine mouthwash, gargle, and nasal spray to reduce nasopharyngeal viral load in patients with COVID-19: a randomized clinical trial. JAMA Otolaryngology–Head & Neck Surgery. 2021 Apr 1;147(4):400-1. [DOI:10.1001/jamaoto.2020.5490]
Di Domênico MB, Cesca H, Ponciano TH, Dos Santos RB, Lenz U, Antunes VP, Godinho VW, Collares K, Corazza PH. Effectiveness of hydrogen peroxide as auxiliary treatment for hospitalized COVID-19 patients in Brazil: preliminary results of a randomized double-blind clinical trial. Epidemiology and health. 2021 May 1;43:e2021032. [DOI:10.4178/epih.e2021032]
Dyer O. Covid-19: Infections climb globally as EG. 5 variant gains ground.[DOI:10.1136/bmj.p1900]
- Abstract Viewed: 207 times
- pdf Downloaded: 85 times